Data from the CENTERSTONE study shows single-dose Xofluza reduces transmission of influenza from an infected person to household members This is the f...
Results delivered in prestigious Proffered Paper oral presentation at ESMO Congress 2024 In patients with any PD-L1 expression (CPS ≥1), efti in co...
Treatment with rinatabart sesutecan (Rina-S) showed encouraging response rate in heavily pretreated patients with ovarian cancer in dose expansion coho...
A discovery led in part by a Texas Biomedical Research Institute (Texas Biomed) Associate Professor has opened the possibility of large-scale manufacturi...
Tolebrutinib meets primary endpoint in HERCULES phase 3 study, the first and only to show reduction in disability accumulation in non-relapsing secondary...
Sustainability: A Key Differentiator as Biopharma Faces Momentum Challenges, Global Survey by Cytiva Reports Companies with a proven commitm...
Mpox is an infectious disease spread through close contact with contagious individuals or infected animals. Most people recover fully, but in some ...
A new survey from Siemens Healthineers and The Harris Poll1 reveals the toll prolonged understaffing is taking on clinical laboratory personnel and the p...
The Biosecure Act is a significant legislative proposal aimed at reshaping the pharmaceutical supply chain landscape, particularly concerning the s...
Johnson & Johnson announced positive results from the nipocalimab Phase 3 Vivacity-MG study in patients with generalized myasthenia gravis (gMG...
Pharmacokinetic data from the CHERISH study suggest that pregnant women treated with certolizumab pegol can maintain their do...
As humans age, hematopoietic stem cells—the immature precursor cells that give rise to all blood and immune cells—accumulate mutations. Some ...
Cancer incidence is expected to rise significantly through 2050, particularly in lower-income countries, to 32 million new cases annually – a pot...
Investing in Global Health for a Safer Future World Health Organization's (WHO) "All for Health, Health for All: Investment Case 2025–2028...
© 2024 Biopharma Boardroom. All Rights Reserved.
